Antithrombin III Deficiency in a Patient with Recurrent Venous Thromboembolism: A Case Report

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2023 Aug 16

PMID 37583989

Authors

Jia-Qing Luo

Shuai-Shuai Mao

Jin-Yi Chen

Xue-Ying Ke

Yue-Feng Zhu

Wei Huang

Hai-Ming Sun

Zhen-Jie Liu

Affiliations

Soon will be listed here.

Abstract

Background: Antithrombin III (AT3) deficiency, an autosomal dominant disease, increases the likelihood of an individual developing venous thromboembolism (VTE). Long-term anticoagulation treatment is required for those suffering from AT3 deficiency.

Case Summary: A man aged 23, who had a history of deep venous thrombosis (DVT), experienced recurrent pain and swelling in his right lower extremity for three days following withdrawal of Rivaroxaban. He was diagnosed with DVT and antithrombin III deficiency as genetic testing revealed a single nucleotide variant in (c.667T>C, p.S223P). The patient was advised to accept long-term anticoagulant therapy.

Conclusion: Inherited AT3 deficiency due to mutations results in recurrent VTE. Patients may benefit from long-term anticoagulant therapy.

Citing Articles

Higher dose of rivaroxaban for the treatment of venous thromboembolism in a 15-year-old Asian child with antithrombin deficiency: A case report and literature review.

Liang C, Chen Y, Liu F, Yue Y, Du L Medicine (Baltimore). 2025; 104(9):e41629.

PMID: 40020143 PMC: 11875584. DOI: 10.1097/MD.0000000000041629.

References

Kawai H, Matsushita H, Kawada H, Ogawa Y, Ando K . The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period. Intern Med. 2017; 56(17):2339-2342. PMC: 5635311. DOI: 10.2169/internalmedicine.8487-16. View

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

Corral J, de la Morena-Barrio M, Vicente V . The genetics of antithrombin. Thromb Res. 2018; 169:23-29. DOI: 10.1016/j.thromres.2018.07.008. View

Mitsuguro M, Sakata T, Okamoto A, Kameda S, Kokubo Y, Tsutsumi Y . Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. Int J Hematol. 2010; 92(3):468-73. DOI: 10.1007/s12185-010-0687-5. View

Alhenc-Gelas M, Plu-Bureau G, Hugon-Rodin J, Picard V, Horellou M . Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. Thromb Haemost. 2017; 117(6):1040-1051. DOI: 10.1160/TH16-08-0635. View

Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J . Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997; 77(3):444-51. View

Navarro-Fernandez J, de la Morena-Barrio M, Padilla J, Minano A, Bohdan N, Aguila S . Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost. 2016; 116(1):146-54. DOI: 10.1160/TH15-11-0871. View

Perry D, Carrell R . Molecular genetics of human antithrombin deficiency. Hum Mutat. 1996; 7(1):7-22. DOI: 10.1002/(SICI)1098-1004(1996)7:1<7::AID-HUMU2>3.0.CO;2-B. View

Wypasek E, Corral J, Alhenc-Gelas M, Sydor W, Iwaniec T, Celinska-Lowenhoff M . Genetic characterization of antithrombin, protein C, and protein S deficiencies in Polish patients. Pol Arch Intern Med. 2017; 127(7-8):512-523. DOI: 10.20452/pamw.4045. View

10.

Picard V, Bura A, Emmerich J, Alhenc-Gelas M, Biron C, Houbouyan-Reveillard L . Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. Br J Haematol. 2000; 110(3):731-4. DOI: 10.1046/j.1365-2141.2000.02245.x. View

11.

Aiach M, Francois D, Priollet P, Capron L, Roncato M, Alhenc-Gelas M . An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy. Br J Haematol. 1987; 66(4):515-22. DOI: 10.1111/j.1365-2141.1987.tb01337.x. View

12.

Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J . Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). Blood Coagul Fibrinolysis. 1998; 9(1):71-8. DOI: 10.1097/00001721-199801000-00009. View

13.

Minami K, Kumagai K, Sugai Y, Nakamura K, Naito S, Oshima S . Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency. Intern Med. 2018; 57(14):2025-2028. PMC: 6096030. DOI: 10.2169/internalmedicine.0483-17. View

14.

Yamaguchi J, Hara N, Yamaguchi T, Nagata Y, Nozato T, Miyamoto T . Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency. J Cardiol Cases. 2018; 16(5):144-147. PMC: 6149282. DOI: 10.1016/j.jccase.2017.06.008. View

15.

Witt D, Nieuwlaat R, Clark N, Ansell J, Holbrook A, Skov J . American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018; 2(22):3257-3291. PMC: 6258922. DOI: 10.1182/bloodadvances.2018024893. View

16.

Mulder R, Croles F, Mulder A, Huntington J, Meijer K, Lukens M . SERPINC1 gene mutations in antithrombin deficiency. Br J Haematol. 2017; 178(2):279-285. DOI: 10.1111/bjh.14658. View